Actovegin solution for injection, 40mg/ml ampoules 5ml 5pcs

Composition

1 ampoule contains:

Active ingredient:

Actovegin ® concentrate (based on dry deproteinized calves ‘ blood hemoderivate)1) – 200.0 mg;

auxiliary substance:

water for injection-up to 5 ml

Pharmacological action

Pharmacotherapy group:

tissue regeneration stimulator

ATX code:

B 06AB

Pharmacological action

Pharmacodynamics

An antihypoxant. Actovegin® is a hemoderivate that is obtained by dialysis and ultrafiltration (compounds with a molecular weight of less than 5000 daltons pass).

It has a positive effect on the transport and utilization of glucose, stimulates oxygen consumption (which leads to stabilization of the plasma membranes of cells in ischemia and reduces the formation of lactate), thus having an antihypoxic effect, which begins to manifest itself no later than 30 minutes after parenteral use and reaches a maximum in an average of 3 hours (2-6 hours). Actovegin ® increases the concentrations of adenosine triphosphate, adenosine diphosphate, phosphocreatine, as well as the amino acids glutamate, aspartate and gamma-aminobutyric acid.

The effect of Actovegin®on oxygen uptake and utilization, as well as insulin-like activity with stimulation of glucose transport and oxidation, are significant in the treatment of diabetic polyneuropathy (DPN). In patients with diabetes mellitus and diabetic polyneuropathy, Actovegin ® significantly reduces the symptoms of polyneuropathy (stabbing pain, burning sensation, parasthesia, numbness in the lower extremities) Objectively, sensitivity disorders decrease, and patients ‘ mental well-being improves.

Pharmacokinetics

It is not possible to study the pharmacokinetic parameters of Actovegin® using pharmacokinetic methods, since it consists only of physiological components that are usually present in the body.

To date, no reduction in the pharmacological effect of hemoderivates has been found in patients with altered pharmacokinetics (for example, hepatic or renal insufficiency, metabolic changes associated with old age, as well as features of metabolism in newborns).

Indications

• Metabolic and vascular disorders of the brain (including ischemic stroke and traumatic brain injury).
• Peripheral (arterial and venous) vascular disorders and their consequences (arterial angiopathy, trophic ulcers); diabetic polyneuropathy
• Wound healing (ulcers of various etiologies, burns, trophic disorders (bedsores) violation of wound healing processes).
• Prevention and treatment of radiation damage to the skin and mucous membranes during radiation therapy

Use during pregnancy and lactation

The use of the drug in pregnant women did not cause negative effects on the mother or fetus.

However, when used in pregnant women, it is necessary to take into account the potential risk to the fetus.

Contraindications

• hypersensitivity to Actovegin® or similar medications.
• decompensated heart failure;
• pulmonary edema;
• oliguria;
• anuria;
• fluid retention in the body.

Side effects

Allergic reactions:

• skin rash;
• hyperemia of the skin;
• hyperthermia, up to anaphylactic shock.

Interaction

Currently unknown.

However, in order to avoid possible pharmaceutical incompatibilities, it is not recommended to add other drugs to the Actovegin infusion solution.

How to take, course of use and dosage

Depending on the severity of the clinical picture, the initial dose is 10-20 ml / day intravenously or intraarterially; then 5 ml intravenously or 5 ml intramuscularly.

Metabolic and vascular disorders of the brain: at the beginning of treatment,10 ml intravenously daily for two weeks, then 5-10 ml intravenously 3-4 times a week for at least 2 weeks.

Ischemic stroke: 20-50 ml in 200-300 ml of the main solution intravenously drip daily for 1 week, then 10-20 ml intravenously drip-2 weeks.

Peripheral (arterial and venous) vascular disorders and their consequences: 20-30 ml of the drug in 200 ml of the main solution intraarterially or intravenously daily; the duration of treatment is about 4 weeks.

Wound healing: 10 ml intravenously or 5 ml intramuscularly daily or 3-4 times a week depending on the healing process (in addition to topical treatment with Actovegin in dosage forms for topical use).

Prevention and treatment of radiation damage to the skin and mucous membranes during radiation therapy: the average dose is 5 ml intravenously daily during breaks in radiation exposure.

Radiation cystitis: daily 10 ml transurethral in combination with antibiotic therapy.

Special instructions

With repeated injections of the solution for infusions, the water-electrolyte balance of blood plasma should be monitored.

The infusion solution and the solution for injection have a slightly yellowish tint. The color intensity may vary from one batch to another depending on the characteristics of the raw materials used, but this does not adversely affect the activity of the drug or its tolerability.

Do not use an opaque solution or a solution containing foreign particles. After opening the bottle (ampoule), the solution should not be stored.

In the case of an intravenous method of use, the drug is administered slowly, no more than 5 ml. Due to the possibility of an anaphylactic reaction, it is recommended to conduct a test injection (2 ml iv).

Form of production

Solution for injection

Storage conditions

In a dark place, at a temperature of 18-25 °C

Active ingredient

Deproteinized calves ‘ blood hemoderivate

Conditions of release from pharmacies

By prescription

Dosage form

solution for injection

Description

For adults as prescribed by a doctor, for pregnant women as prescribed by a doctor

Indications

Acquired dementia, Trophic ulcers, Pressure Sores, Concussion and other traumatic brain injuries, Wounds, Burns, Cerebral circulation disorders, Stroke consequences